Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

The fitness cost of the genes responsible for resistance to fluoroquinolones in clinical isolates of Streptococcus pneumoniae were estimated in vitro in a common genetic background. Naturally occurring parC, parE, and gyrA loci containing mutations in the quinolone-resistance-determining regions were introduced by transformation into S. pneumoniae strain R6 individually and in combinations. The fitness of these transformants was estimated by pairwise competition experiments with a common R6 strain. On average, single par and gyr mutants responsible for low-level MIC resistance (first-step resistance) impose a fitness burden of approximately 8%. Some of these mutants engender no measurable cost, while one, a parE mutant, reduces the fitness of these bacteria by more than 40%. Most interestingly, the addition of the second par or gyr mutations required for clinically significant, high-MIC fluoroquinolone resistance does not increase the fitness burden imposed by these single genes and can even reduce it. We discuss the implications of these results for the epidemiology of fluoroquinolone resistance and the evolution of acquired resistance in treated patients.

Knowledge Graph

Similar Paper

Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae
Antimicrobial Agents and Chemotherapy 2007.0
Fitness of Streptococcus pneumoniae Fluoroquinolone-Resistant Strains with Topoisomerase IV Recombinant Genes
Antimicrobial Agents and Chemotherapy 2008.0
Fluoroquinolone-Resistant Mutants ofBurkholderia cepacia
Antimicrobial Agents and Chemotherapy 2008.0
Real-Time PCR Detection of gyrA and parC Mutations in Streptococcus pneumoniae
Antimicrobial Agents and Chemotherapy 2008.0
First Characterization of Fluoroquinolone Resistance in Streptococcus suis
Antimicrobial Agents and Chemotherapy 2007.0
Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in Escherichia coli
Antimicrobial Agents and Chemotherapy 2007.0
Fitness Costs and Stability of a High-Level Ciprofloxacin Resistance Phenotype in Salmonella enterica Serotype Enteritidis: Reduced Infectivity Associated with Decreased Expression of Salmonella Pathogenicity Island 1 Genes
Antimicrobial Agents and Chemotherapy 2010.0
Fluoroquinolone Resistance in Atypical Pneumococci and Oral Streptococci: Evidence of Horizontal Gene Transfer of Fluoroquinolone Resistance Determinants from Streptococcus pneumoniae
Antimicrobial Agents and Chemotherapy 2007.0
Emergence of Fluoroquinolone Resistance in Group B Streptococcal Isolates in Taiwan
Antimicrobial Agents and Chemotherapy 2008.0
Interspecies Recombination Occurs Frequently in Quinolone Resistance-Determining Regions of Clinical Isolates of Streptococcus pyogenes
Antimicrobial Agents and Chemotherapy 2008.0